Why the study?
Survival outcomes in patients with head and neck synovial sarcoma, particularly those presenting with localized disease at diagnosis, needed to be evaluated.
Does perioperative radiation therapy and chemotherapy improve survival outcomes in patients with localized primary head and neck synovial sarcoma compared to surgery alone?
Does perioperative radiation therapy and chemotherapy improve survival outcomes in patients with localized primary head and neck synovial sarcoma compared to surgery alone?
In patients with localized primary head and neck synovial sarcoma, perioperative radiation therapy improves local control and perioperative chemotherapy delays metastasis, particularly for tumors ≥ 4 cm.
Answers are grounded in this paper and cite their sources.
Favorable localized HNSS outcomes with RT; leaves open optimal chemotherapy role and generalizability in prospective studies.
Background: this study aims to evaluate the survival outcomes of patients suffering from head and neck synovial sarcoma (HNSS), especially in relation to patients with a localized disease at diagnosis. Methods: this retrospective chart review includes 57 patients diagnosed with primary HNSS between 1981 and 2020 who presented with a localized disease at diagnosis. Overall survival (OS) from diagnosis, local recurrence-free survival (LRFS), and metastasis-free survival (MFS) from the end of the primary tumor treatment are estimated. The Kaplan–Meier method, the log-rank test, and the Cox proportional hazards regression are used. Results: the 5-year OS, LRFS, and MFS are estimated at 80.4% (95% CI: 66.6%, 88.9%), 67.7% (95% CI: 50.0%, 80.4%), and 50.6% (95% CI: 34.4%, 64.8), respectively. Compared to patients undergoing surgical resection alone, those receiving radiation therapy (RT) with surgery have better LRFS (HR: 0.03, 95% CI: 0.001, 0.57), and those undergoing neo/adjuvant chemotherapy with surgery and RT have better MFS (HR: 0.10, 95% CI: 0.01, 0.95). Moreover, among the patients with tumors ≥ 4 cm, those subject to neo/adjuvant chemotherapy have significantly better MFS (5-year MFS: 53.2%, 95% CI: 29.0%, 72.5%) than those treated with surgery and RT alone (5-year MFS: 20.0%, 95% CI: 0.8%, 58.2%) (LR-p = 0.003). Conclusions: overall, the prognosis of HNSS patients looks favorable. Perioperative RT significantly improves local control, and perioperative chemotherapy plays a vital role in delaying metastasis formation in patients with primary HNSS when diagnosed with a localized disease. Importantly, we recommend that systemic therapy should be considered for HNSS patients with tumors ≥ 4 cm.
No takes yet. Share an insight, caveat, or question.
Patel et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: